{"id":349750,"date":"2025-08-25T18:20:39","date_gmt":"2025-08-25T18:20:39","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-immunovant\/"},"modified":"2025-08-25T18:20:39","modified_gmt":"2025-08-25T18:20:39","slug":"how-to-buy-immunovant","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/","title":{"rendered":"Immunovant, Inc. (IMVT) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Immunovant, Inc. (IMVT) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334072,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-349750","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Immunovant, Inc. (IMVT) Hisseleri Nas\u0131l Al\u0131n\u0131r - Immunovant, Inc. (IMVT) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Immunovant, Inc. (IMVT) Hisseleri Nas\u0131l Al\u0131n\u0131r - Immunovant, Inc. (IMVT) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Immunovant, Inc. (IMVT) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 ve bu klinik a\u015famadaki biyoteknoloji \u015firketine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin. G\u00fcncel hisse performans\u0131n\u0131, fiyat tahminlerini ve 2025 i\u00e7in ticaret stratejilerini ke\u015ffedin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Immunovant, Inc. (IMVT) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 ve bu klinik a\u015famadaki biyoteknoloji \u015firketine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin. G\u00fcncel hisse performans\u0131n\u0131, fiyat tahminlerini ve 2025 i\u00e7in ticaret stratejilerini ke\u015ffedin."},"intro":"Otoimm\u00fcn hastal\u0131k tedavilerinin gelece\u011fine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Immunovant, 2025'in en heyecan verici klinik a\u015famadaki biyoteknoloji f\u0131rsatlar\u0131ndan birini temsil ediyor. Alt\u0131 potansiyel kay\u0131t denemesi devam etmekte ve 2027'ye kadar nakit runway ile bu \u015firket, Graves hastal\u0131\u011f\u0131 ve romatoid artrit gibi durumlar\u0131n tedavisinde devrim yaratabilir. IMVT hissesinin neden dikkatinizi hak etti\u011fini birlikte ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"Otoimm\u00fcn hastal\u0131k tedavilerinin gelece\u011fine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Immunovant, 2025'in en heyecan verici klinik a\u015famadaki biyoteknoloji f\u0131rsatlar\u0131ndan birini temsil ediyor. Alt\u0131 potansiyel kay\u0131t denemesi devam etmekte ve 2027'ye kadar nakit runway ile bu \u015firket, Graves hastal\u0131\u011f\u0131 ve romatoid artrit gibi durumlar\u0131n tedavisinde devrim yaratabilir. IMVT hissesinin neden dikkatinizi hak etti\u011fini birlikte ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 Immunovant Hisse Analizi: G\u00fcncel Fiyat ve Piyasa Konumu<\/h2> <p>25 A\u011fustos 2025 itibar\u0131yla Immunovant, Inc. (IMVT) NASDAQ'ta <strong>15,24 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Bu fiyat, \u015firketin klinik ilerlemesi ve analist iyimserli\u011fi g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda ilgi \u00e7ekici bir giri\u015f noktas\u0131 sunuyor.<\/p> <p><strong>Takviminizi \u0130\u015faretleyin: Eyl\u00fcl 2025 Kritik!<\/strong><\/p> <p>Amerikan Tiroid Derne\u011fi Y\u0131ll\u0131k Toplant\u0131s\u0131 Eyl\u00fcl 2025'te IMVT hissedarlar\u0131 i\u00e7in oyunun kurallar\u0131n\u0131 de\u011fi\u015ftirebilir. Immunovant, Graves hastal\u0131\u011f\u0131nda batoclimab kavram kan\u0131t\u0131 \u00e7al\u0131\u015fmas\u0131ndan remisyon verilerini sunacak (<a href=\"https:\/\/www.immunovant.com\/investors\/news-events\/press-releases\/detail\/66\/immunovant-announces-oral-presentation-of-late-breaking\">Immunovant Bas\u0131n B\u00fclteni<\/a>).<\/p> <p>Tarihsel veriler, bu t\u0131bbi konferans sunumlar\u0131n\u0131n biyoteknoloji hisselerini dramatik \u015fekilde hareket ettirebilece\u011fini g\u00f6steriyor. Immunovant, Eyl\u00fcl 2024'te Graves hastal\u0131\u011f\u0131 hastalar\u0131nda %76 yan\u0131t oran\u0131 g\u00f6steren olumlu Faz 2a sonu\u00e7lar\u0131n\u0131 bildirdi\u011finde hisse \u00f6nemli dalgalanma ya\u015fad\u0131. Yakla\u015fan Eyl\u00fcl 2025 verileri, kavram kan\u0131t\u0131 remisyon verisi olmas\u0131 nedeniyle daha b\u00fcy\u00fck hareketleri tetikleyebilir.<\/p> <p><strong>6 Ayl\u0131k Fiyat Yolculu\u011fu: Dalgal\u0131 ve \u0130yile\u015fme \u0130\u015faretleri<\/strong><\/p> <p>Immunovant, 2025 y\u0131l\u0131nda yat\u0131r\u0131mc\u0131lar\u0131 olduk\u00e7a hareketli bir yolculu\u011fa \u00e7\u0131kard\u0131:<\/p> <table border=\"1\" cellspacing=\"0\" cellpadding=\"5\"> <thead> <tr> <th>Ay<\/th> <th>Y\u00fcksek<\/th> <th>D\u00fc\u015f\u00fck<\/th> <th>% De\u011fi\u015fim<\/th> <th>\u00d6nemli Geli\u015fme<\/th> <\/tr> <\/thead> <tbody> <tr> <td>\u015eubat<\/td> <td>23,11 $<\/td> <td>19,07 $<\/td> <td>-%5,24<\/td> <td>Y\u0131l ba\u015f\u0131 konsolidasyonu<\/td> <\/tr> <tr> <td>Mart<\/td> <td>20,70 $<\/td> <td>16,72 $<\/td> <td>-17,04%<\/td> <td>Geni\u015f piyasa biyoteknoloji zay\u0131fl\u0131\u011f\u0131<\/td> <\/tr> <tr> <td>Nisan<\/td> <td>17,09 $<\/td> <td>12,72 $<\/td> <td>-5,50%<\/td> <td>52 haftal\u0131k dip seviyesi<\/td> <\/tr> <tr> <td>May\u0131s<\/td> <td>16,44 $<\/td> <td>13,36 $<\/td> <td>-8,05%<\/td> <td>Devam eden bask\u0131<\/td> <\/tr> <tr> <td>Haziran<\/td> <td>17,14 $<\/td> <td>14,58 $<\/td> <td>+7,74%<\/td> <td>\u0130yile\u015fme belirtileri<\/td> <\/tr> <tr> <td>Temmuz<\/td> <td>19,06 $<\/td> <td>15,31 $<\/td> <td>+5,94%<\/td> <td>Yukar\u0131 y\u00f6nl\u00fc momentum devam ediyor<\/td> <\/tr> <\/tbody> <\/table> <p>Hisse, Ocak zirvelerinden May\u0131s diplerine yakla\u015f\u0131k %37 d\u00fc\u015ft\u00fc ancak Nisan diplerinden itibaren yakla\u015f\u0131k %15'lik cesaret verici bir toparlanma g\u00f6sterdi. Hacim desenleri, zay\u0131fl\u0131k d\u00f6neminde kurumsal birikimi i\u015faret ediyor.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist konsens\u00fcs\u00fc ve klinik kilometre ta\u015flar\u0131na dayanarak, beklenenler \u015funlard\u0131r:<\/p> <p><strong>2025 Y\u0131l Sonu:<\/strong> 18-22 $ aral\u0131\u011f\u0131 (potansiyel %18-44 y\u00fckseli\u015f)<br> Eyl\u00fcl ATA toplant\u0131s\u0131 verileri, IMVT'yi bu aral\u0131\u011f\u0131n \u00fcst s\u0131n\u0131r\u0131na itebilir.<\/p> <p><strong>2026 Tahmini:<\/strong> 30-38 $ hedef aral\u0131\u011f\u0131<br> <a href=\"https:\/\/www.tipranks.com\/stocks\/imvt\/forecast\">TipRanks<\/a> analistleri, %148 y\u00fckseli\u015f potansiyeliyle ortalama 37,83 $ fiyat hedefi \u00f6ng\u00f6r\u00fcyor.<\/p> <p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc:<\/strong> 45-65 $ potansiyel aral\u0131\u011f\u0131<br> 2028'e kadar alt\u0131 endikasyonda birden fazla klinik sonu\u00e7, denemeler ba\u015far\u0131l\u0131 olursa \u00f6nemli de\u011fer yaratabilir.<\/p> <p><strong>2030 Vizyonu:<\/strong> 50-80 $ uzun vadeli potansiyel<br> Stockscan.io, ba\u015far\u0131l\u0131 y\u00fcr\u00fctme devam ederse 2030 i\u00e7in ortalama 64,16 $ fiyat tahmin ediyor.<\/p> <p><strong>Karar: R\u0130SK TOLERANSI OLAN YATIRIMCILAR \u0130\u00c7\u0130N G\u00dc\u00c7L\u00dc ALIM<\/strong><br> 2027'ye kadar nakit runway ve \u00e7oklu klinik kataliz\u00f6rler g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda risk-getiri oran\u0131 olduk\u00e7a olumlu g\u00f6r\u00fcn\u00fcyor.<\/p> <h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2> <p><strong>Dikkate Al\u0131nmas\u0131 Gereken Riskler:<\/strong><\/p> <ul> <li>Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131 (biyoteknolojinin s\u00fcrekli riski)<\/li> <li>Yeni otoimm\u00fcn tedaviler i\u00e7in d\u00fczenleyici engeller<\/li> <li>\u00c7eyrek ba\u015f\u0131na yakla\u015f\u0131k 100 milyon $ nakit t\u00fcketimi<\/li> <li>Gelir \u00f6ncesi biyoteknolojiye \u00f6zg\u00fc y\u00fcksek volatilite<\/li> <li>FcRn inhibit\u00f6r\u00fc alan\u0131nda rekabet\u00e7i ortam<\/li> <\/ul> <p><strong>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar:<\/strong><\/p> <ul> <li>Alt\u0131 potansiyel kay\u0131t denemesi devam ediyor<\/li> <li>2027'ye kadar 714 milyon $ nakit runway (<a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/05\/29\/3090173\/0\/en\/Immunovant-Provides-Corporate-Updates-and-Reports-Financial-Results-for-the-Fourth-Quarter-and-Fiscal-Year-Ended-March-31-2025.html\">2025 Mali Y\u0131l\u0131 4. \u00c7eyrek Raporu<\/a>)<\/li> <li>Eyl\u00fcl 2025 Graves hastal\u0131\u011f\u0131 veri kataliz\u00f6r\u00fc<\/li> <li>Eric Venker'in CEO olarak yeni liderli\u011fi<\/li> <li>Sekt\u00f6r trendi: otoimm\u00fcn hastal\u0131k pazar\u0131 %9 CAGR ile b\u00fcy\u00fcyor<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong> - Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-5'inden fazlas\u0131n\u0131 IMVT gibi y\u00fcksek riskli biyoteknolojiye ay\u0131rmay\u0131n<\/li> <li><strong>Ortalama Maliyetle Al\u0131m<\/strong> - Zamanlama riskini azaltmak i\u00e7in toplu de\u011fil par\u00e7a par\u00e7a sat\u0131n al\u0131n<\/li> <li><strong>Eyl\u00fcl \u0130\u00e7in Uyar\u0131 Kurun<\/strong> - ATA toplant\u0131s\u0131 volatiliteyle m\u00fckemmel giri\u015f noktalar\u0131 sa\u011flayabilir<\/li> <li><strong>Uzun Vadeli D\u00fc\u015f\u00fcn\u00fcn<\/strong> - Biyoteknoloji yat\u0131r\u0131m\u0131 klinik kilometre ta\u015flar\u0131 boyunca sab\u0131r gerektirir<\/li> <\/ol> <p>Mizahi t\u00fcccar bilgeli\u011fi: \"\u015eimdi IMVT almak, hen\u00fcz duyurulmam\u0131\u015f bir konsere backstage bileti almak gibidir. Baz\u0131 s\u0131k\u0131c\u0131 a\u00e7\u0131l\u0131\u015f performanslar\u0131n\u0131 bekleyebilirsiniz, ama ba\u015frol sahneye \u00e7\u0131kt\u0131\u011f\u0131nda...\"<\/p> <h2>\u2705 Immunovant, Inc. (IMVT) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table border=\"1\" cellspacing=\"0\" cellpadding=\"5\"> <thead> <tr> <th>Ad\u0131m<\/th> <th>\u0130\u015flem<\/th> <th>Neden \u00d6nemli<\/th> <\/tr> <\/thead> <tbody> <tr> <td>1<\/td> <td>Bir Ticaret Platformu Se\u00e7in<\/td> <td>NASDAQ listeleri ve kesirli hisse sunan bir platform oldu\u011fundan emin olun<\/td> <\/tr> <tr> <td>2<\/td> <td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td> <td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td> <\/tr> <tr> <td>3<\/td> <td>\"IMVT\" Aramas\u0131 Yap\u0131n<\/td> <td>Immunovant i\u00e7in tam sembol\u00fc kullan\u0131n<\/td> <\/tr> <tr> <td>4<\/td> <td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td> <td>Giri\u015f fiyat\u0131n\u0131z\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td> <\/tr> <tr> <td>5<\/td> <td>\u0130nceleyin ve Onaylay\u0131n<\/td> <td>Emir detaylar\u0131n\u0131 y\u00fcr\u00fctmeden \u00f6nce \u00e7ift kontrol edin<\/td> <\/tr> <tr> <td>6<\/td> <td>Pozisyonunuzu \u0130zleyin<\/td> <td>\u00d6nemli seviyeler i\u00e7in fiyat uyar\u0131lar\u0131 kurun<\/td> <\/tr> <tr> <td>7<\/td> <td>\u00c7\u0131k\u0131\u015f Stratejinizi Planlay\u0131n<\/td> <td>K\u00e2r alma ve zarar durdurma seviyelerini \u00f6nceden belirleyin<\/td> <\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Neden Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Uygun?<\/h2> <p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flamak isteyenler i\u00e7in Pocket Option birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Sadece 5 $ minimum depozito<\/strong> - Stratejileri d\u00fc\u015f\u00fck riskle test etmek i\u00e7in ideal<\/li> <li><strong>1 dakikal\u0131k KYC s\u00fcreci<\/strong> - Herhangi bir kimlik belgesini y\u00fckleyip hemen i\u015flem yapmaya ba\u015flay\u0131n<\/li> <li><strong>100+ para \u00e7ekme y\u00f6ntemi<\/strong> - Kripto, e-c\u00fczdan ve banka kartlar\u0131 ile esneklik<\/li> <li><strong>Kesirli hisse ticareti<\/strong> - IMVT gibi pahal\u0131 hisselerin par\u00e7alar\u0131n\u0131 sat\u0131n al\u0131n<\/li> <\/ul> <p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, daha b\u00fcy\u00fck miktarlara ge\u00e7meden \u00f6nce g\u00fcven kazanmak isteyen yeni ba\u015flayanlar i\u00e7in idealdir.<\/p> <h2>\ud83c\udf0d 2025'te Immunovant: Otoimm\u00fcn Hastal\u0131kta Yenilik\u00e7i<\/h2> <p>Immunovant, otoimm\u00fcn hastal\u0131k tedavisi geli\u015ftirmede \u00f6nc\u00fc konumdad\u0131r. \u015eirketin lider \u00fcr\u00fcn\u00fc IMVT-1402, Graves hastal\u0131\u011f\u0131, romatoid artrit ve miyastenia gravis gibi milyonlarca hastan\u0131n tedavisini d\u00f6n\u00fc\u015ft\u00fcrebilecek potansiyel en iyi s\u0131n\u0131f FcRn inhibit\u00f6r\u00fcd\u00fcr.<\/p> <ul> <li><strong>Mevcut Piyasa Konumu:<\/strong> Alt\u0131 aktif geli\u015ftirme program\u0131 olan klinik a\u015famadaki biyoteknoloji \u015firketi<\/li> <li><strong>Nakit Runway:<\/strong> Beklenen 2027 veri sonu\u00e7lar\u0131na kadar yakla\u015f\u0131k 714 milyon $<\/li> <li><strong>Liderlik:<\/strong> Nisan 2025 ge\u00e7i\u015finden beri CEO Dr. Eric Venker<\/li> <\/ul> <p><strong>\u0130lgin\u00e7 Bilgi:<\/strong> Haziran 2025'te Immunovant, Graves hastal\u0131\u011f\u0131 VE Sj\u00f6gren hastal\u0131\u011f\u0131 i\u00e7in e\u015f zamanl\u0131 olarak iki potansiyel kay\u0131t denemesini ba\u015flatan az say\u0131daki biyoteknoloji \u015firketinden biri oldu. Bu agresif paralel geli\u015ftirme stratejisi sekt\u00f6rde nispeten nadirdir ve platform teknolojilerine olan g\u00fcveni g\u00f6sterir.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Immunovant Hisse Analizi: G\u00fcncel Fiyat ve Piyasa Konumu<\/h2>\n<p>25 A\u011fustos 2025 itibar\u0131yla Immunovant, Inc. (IMVT) NASDAQ&#8217;ta <strong>15,24 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Bu fiyat, \u015firketin klinik ilerlemesi ve analist iyimserli\u011fi g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda ilgi \u00e7ekici bir giri\u015f noktas\u0131 sunuyor.<\/p>\n<p><strong>Takviminizi \u0130\u015faretleyin: Eyl\u00fcl 2025 Kritik!<\/strong><\/p>\n<p>Amerikan Tiroid Derne\u011fi Y\u0131ll\u0131k Toplant\u0131s\u0131 Eyl\u00fcl 2025&#8217;te IMVT hissedarlar\u0131 i\u00e7in oyunun kurallar\u0131n\u0131 de\u011fi\u015ftirebilir. Immunovant, Graves hastal\u0131\u011f\u0131nda batoclimab kavram kan\u0131t\u0131 \u00e7al\u0131\u015fmas\u0131ndan remisyon verilerini sunacak (<a href=\"https:\/\/www.immunovant.com\/investors\/news-events\/press-releases\/detail\/66\/immunovant-announces-oral-presentation-of-late-breaking\">Immunovant Bas\u0131n B\u00fclteni<\/a>).<\/p>\n<p>Tarihsel veriler, bu t\u0131bbi konferans sunumlar\u0131n\u0131n biyoteknoloji hisselerini dramatik \u015fekilde hareket ettirebilece\u011fini g\u00f6steriyor. Immunovant, Eyl\u00fcl 2024&#8217;te Graves hastal\u0131\u011f\u0131 hastalar\u0131nda %76 yan\u0131t oran\u0131 g\u00f6steren olumlu Faz 2a sonu\u00e7lar\u0131n\u0131 bildirdi\u011finde hisse \u00f6nemli dalgalanma ya\u015fad\u0131. Yakla\u015fan Eyl\u00fcl 2025 verileri, kavram kan\u0131t\u0131 remisyon verisi olmas\u0131 nedeniyle daha b\u00fcy\u00fck hareketleri tetikleyebilir.<\/p>\n<p><strong>6 Ayl\u0131k Fiyat Yolculu\u011fu: Dalgal\u0131 ve \u0130yile\u015fme \u0130\u015faretleri<\/strong><\/p>\n<p>Immunovant, 2025 y\u0131l\u0131nda yat\u0131r\u0131mc\u0131lar\u0131 olduk\u00e7a hareketli bir yolculu\u011fa \u00e7\u0131kard\u0131:<\/p>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"5\">\n<thead>\n<tr>\n<th>Ay<\/th>\n<th>Y\u00fcksek<\/th>\n<th>D\u00fc\u015f\u00fck<\/th>\n<th>% De\u011fi\u015fim<\/th>\n<th>\u00d6nemli Geli\u015fme<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>\u015eubat<\/td>\n<td>23,11 $<\/td>\n<td>19,07 $<\/td>\n<td>-%5,24<\/td>\n<td>Y\u0131l ba\u015f\u0131 konsolidasyonu<\/td>\n<\/tr>\n<tr>\n<td>Mart<\/td>\n<td>20,70 $<\/td>\n<td>16,72 $<\/td>\n<td>-17,04%<\/td>\n<td>Geni\u015f piyasa biyoteknoloji zay\u0131fl\u0131\u011f\u0131<\/td>\n<\/tr>\n<tr>\n<td>Nisan<\/td>\n<td>17,09 $<\/td>\n<td>12,72 $<\/td>\n<td>-5,50%<\/td>\n<td>52 haftal\u0131k dip seviyesi<\/td>\n<\/tr>\n<tr>\n<td>May\u0131s<\/td>\n<td>16,44 $<\/td>\n<td>13,36 $<\/td>\n<td>-8,05%<\/td>\n<td>Devam eden bask\u0131<\/td>\n<\/tr>\n<tr>\n<td>Haziran<\/td>\n<td>17,14 $<\/td>\n<td>14,58 $<\/td>\n<td>+7,74%<\/td>\n<td>\u0130yile\u015fme belirtileri<\/td>\n<\/tr>\n<tr>\n<td>Temmuz<\/td>\n<td>19,06 $<\/td>\n<td>15,31 $<\/td>\n<td>+5,94%<\/td>\n<td>Yukar\u0131 y\u00f6nl\u00fc momentum devam ediyor<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Hisse, Ocak zirvelerinden May\u0131s diplerine yakla\u015f\u0131k %37 d\u00fc\u015ft\u00fc ancak Nisan diplerinden itibaren yakla\u015f\u0131k %15&#8217;lik cesaret verici bir toparlanma g\u00f6sterdi. Hacim desenleri, zay\u0131fl\u0131k d\u00f6neminde kurumsal birikimi i\u015faret ediyor.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist konsens\u00fcs\u00fc ve klinik kilometre ta\u015flar\u0131na dayanarak, beklenenler \u015funlard\u0131r:<\/p>\n<p><strong>2025 Y\u0131l Sonu:<\/strong> 18-22 $ aral\u0131\u011f\u0131 (potansiyel %18-44 y\u00fckseli\u015f)<br \/> Eyl\u00fcl ATA toplant\u0131s\u0131 verileri, IMVT&#8217;yi bu aral\u0131\u011f\u0131n \u00fcst s\u0131n\u0131r\u0131na itebilir.<\/p>\n<p><strong>2026 Tahmini:<\/strong> 30-38 $ hedef aral\u0131\u011f\u0131<br \/> <a href=\"https:\/\/www.tipranks.com\/stocks\/imvt\/forecast\">TipRanks<\/a> analistleri, %148 y\u00fckseli\u015f potansiyeliyle ortalama 37,83 $ fiyat hedefi \u00f6ng\u00f6r\u00fcyor.<\/p>\n<p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc:<\/strong> 45-65 $ potansiyel aral\u0131\u011f\u0131<br \/> 2028&#8217;e kadar alt\u0131 endikasyonda birden fazla klinik sonu\u00e7, denemeler ba\u015far\u0131l\u0131 olursa \u00f6nemli de\u011fer yaratabilir.<\/p>\n<p><strong>2030 Vizyonu:<\/strong> 50-80 $ uzun vadeli potansiyel<br \/> Stockscan.io, ba\u015far\u0131l\u0131 y\u00fcr\u00fctme devam ederse 2030 i\u00e7in ortalama 64,16 $ fiyat tahmin ediyor.<\/p>\n<p><strong>Karar: R\u0130SK TOLERANSI OLAN YATIRIMCILAR \u0130\u00c7\u0130N G\u00dc\u00c7L\u00dc ALIM<\/strong><br \/> 2027&#8217;ye kadar nakit runway ve \u00e7oklu klinik kataliz\u00f6rler g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda risk-getiri oran\u0131 olduk\u00e7a olumlu g\u00f6r\u00fcn\u00fcyor.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2>\n<p><strong>Dikkate Al\u0131nmas\u0131 Gereken Riskler:<\/strong><\/p>\n<ul>\n<li>Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131 (biyoteknolojinin s\u00fcrekli riski)<\/li>\n<li>Yeni otoimm\u00fcn tedaviler i\u00e7in d\u00fczenleyici engeller<\/li>\n<li>\u00c7eyrek ba\u015f\u0131na yakla\u015f\u0131k 100 milyon $ nakit t\u00fcketimi<\/li>\n<li>Gelir \u00f6ncesi biyoteknolojiye \u00f6zg\u00fc y\u00fcksek volatilite<\/li>\n<li>FcRn inhibit\u00f6r\u00fc alan\u0131nda rekabet\u00e7i ortam<\/li>\n<\/ul>\n<p><strong>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar:<\/strong><\/p>\n<ul>\n<li>Alt\u0131 potansiyel kay\u0131t denemesi devam ediyor<\/li>\n<li>2027&#8217;ye kadar 714 milyon $ nakit runway (<a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/05\/29\/3090173\/0\/en\/Immunovant-Provides-Corporate-Updates-and-Reports-Financial-Results-for-the-Fourth-Quarter-and-Fiscal-Year-Ended-March-31-2025.html\">2025 Mali Y\u0131l\u0131 4. \u00c7eyrek Raporu<\/a>)<\/li>\n<li>Eyl\u00fcl 2025 Graves hastal\u0131\u011f\u0131 veri kataliz\u00f6r\u00fc<\/li>\n<li>Eric Venker&#8217;in CEO olarak yeni liderli\u011fi<\/li>\n<li>Sekt\u00f6r trendi: otoimm\u00fcn hastal\u0131k pazar\u0131 %9 CAGR ile b\u00fcy\u00fcyor<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong> &#8211; Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-5&#8217;inden fazlas\u0131n\u0131 IMVT gibi y\u00fcksek riskli biyoteknolojiye ay\u0131rmay\u0131n<\/li>\n<li><strong>Ortalama Maliyetle Al\u0131m<\/strong> &#8211; Zamanlama riskini azaltmak i\u00e7in toplu de\u011fil par\u00e7a par\u00e7a sat\u0131n al\u0131n<\/li>\n<li><strong>Eyl\u00fcl \u0130\u00e7in Uyar\u0131 Kurun<\/strong> &#8211; ATA toplant\u0131s\u0131 volatiliteyle m\u00fckemmel giri\u015f noktalar\u0131 sa\u011flayabilir<\/li>\n<li><strong>Uzun Vadeli D\u00fc\u015f\u00fcn\u00fcn<\/strong> &#8211; Biyoteknoloji yat\u0131r\u0131m\u0131 klinik kilometre ta\u015flar\u0131 boyunca sab\u0131r gerektirir<\/li>\n<\/ol>\n<p>Mizahi t\u00fcccar bilgeli\u011fi: &#8220;\u015eimdi IMVT almak, hen\u00fcz duyurulmam\u0131\u015f bir konsere backstage bileti almak gibidir. Baz\u0131 s\u0131k\u0131c\u0131 a\u00e7\u0131l\u0131\u015f performanslar\u0131n\u0131 bekleyebilirsiniz, ama ba\u015frol sahneye \u00e7\u0131kt\u0131\u011f\u0131nda&#8230;&#8221;<\/p>\n<h2>\u2705 Immunovant, Inc. (IMVT) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"5\">\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir Ticaret Platformu Se\u00e7in<\/td>\n<td>NASDAQ listeleri ve kesirli hisse sunan bir platform oldu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td>\n<td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;IMVT&#8221; Aramas\u0131 Yap\u0131n<\/td>\n<td>Immunovant i\u00e7in tam sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td>\n<td>Giri\u015f fiyat\u0131n\u0131z\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130nceleyin ve Onaylay\u0131n<\/td>\n<td>Emir detaylar\u0131n\u0131 y\u00fcr\u00fctmeden \u00f6nce \u00e7ift kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Pozisyonunuzu \u0130zleyin<\/td>\n<td>\u00d6nemli seviyeler i\u00e7in fiyat uyar\u0131lar\u0131 kurun<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>\u00c7\u0131k\u0131\u015f Stratejinizi Planlay\u0131n<\/td>\n<td>K\u00e2r alma ve zarar durdurma seviyelerini \u00f6nceden belirleyin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Neden Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Uygun?<\/h2>\n<p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flamak isteyenler i\u00e7in Pocket Option birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Sadece 5 $ minimum depozito<\/strong> &#8211; Stratejileri d\u00fc\u015f\u00fck riskle test etmek i\u00e7in ideal<\/li>\n<li><strong>1 dakikal\u0131k KYC s\u00fcreci<\/strong> &#8211; Herhangi bir kimlik belgesini y\u00fckleyip hemen i\u015flem yapmaya ba\u015flay\u0131n<\/li>\n<li><strong>100+ para \u00e7ekme y\u00f6ntemi<\/strong> &#8211; Kripto, e-c\u00fczdan ve banka kartlar\u0131 ile esneklik<\/li>\n<li><strong>Kesirli hisse ticareti<\/strong> &#8211; IMVT gibi pahal\u0131 hisselerin par\u00e7alar\u0131n\u0131 sat\u0131n al\u0131n<\/li>\n<\/ul>\n<p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, daha b\u00fcy\u00fck miktarlara ge\u00e7meden \u00f6nce g\u00fcven kazanmak isteyen yeni ba\u015flayanlar i\u00e7in idealdir.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te Immunovant: Otoimm\u00fcn Hastal\u0131kta Yenilik\u00e7i<\/h2>\n<p>Immunovant, otoimm\u00fcn hastal\u0131k tedavisi geli\u015ftirmede \u00f6nc\u00fc konumdad\u0131r. \u015eirketin lider \u00fcr\u00fcn\u00fc IMVT-1402, Graves hastal\u0131\u011f\u0131, romatoid artrit ve miyastenia gravis gibi milyonlarca hastan\u0131n tedavisini d\u00f6n\u00fc\u015ft\u00fcrebilecek potansiyel en iyi s\u0131n\u0131f FcRn inhibit\u00f6r\u00fcd\u00fcr.<\/p>\n<ul>\n<li><strong>Mevcut Piyasa Konumu:<\/strong> Alt\u0131 aktif geli\u015ftirme program\u0131 olan klinik a\u015famadaki biyoteknoloji \u015firketi<\/li>\n<li><strong>Nakit Runway:<\/strong> Beklenen 2027 veri sonu\u00e7lar\u0131na kadar yakla\u015f\u0131k 714 milyon $<\/li>\n<li><strong>Liderlik:<\/strong> Nisan 2025 ge\u00e7i\u015finden beri CEO Dr. Eric Venker<\/li>\n<\/ul>\n<p><strong>\u0130lgin\u00e7 Bilgi:<\/strong> Haziran 2025&#8217;te Immunovant, Graves hastal\u0131\u011f\u0131 VE Sj\u00f6gren hastal\u0131\u011f\u0131 i\u00e7in e\u015f zamanl\u0131 olarak iki potansiyel kay\u0131t denemesini ba\u015flatan az say\u0131daki biyoteknoloji \u015firketinden biri oldu. Bu agresif paralel geli\u015ftirme stratejisi sekt\u00f6rde nispeten nadirdir ve platform teknolojilerine olan g\u00fcveni g\u00f6sterir.<\/p>\n"},"faq":[{"question":"Immunovant hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \"IMVT\" sembol\u00fcn\u00fc aray\u0131n, limit emirleri kullanarak al\u0131m yap\u0131n ve pozisyonunuzu izleyin."},{"question":"Immunovant'\u0131n 2025 fiyat tahmini nedir?","answer":"2025 y\u0131l sonu i\u00e7in 18-22 $ aral\u0131\u011f\u0131nda fiyat bekleniyor, bu da %18-44 aras\u0131nda potansiyel y\u00fckseli\u015f anlam\u0131na geliyor."},{"question":"Immunovant'\u0131n en b\u00fcy\u00fck riskleri nelerdir?","answer":"Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, d\u00fczenleyici engeller, y\u00fcksek nakit t\u00fcketimi ve biyoteknoloji sekt\u00f6r\u00fcne \u00f6zg\u00fc volatilite ba\u015fl\u0131ca risklerdir."},{"question":"Yeni ba\u015flayanlar i\u00e7in yat\u0131r\u0131m \u00f6nerileri nelerdir?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir k\u0131sm\u0131yla ba\u015flay\u0131n, dolar maliyeti ortalamas\u0131 yap\u0131n, \u00f6nemli tarihler i\u00e7in uyar\u0131lar kurun ve uzun vadeli d\u00fc\u015f\u00fcn\u00fcn."},{"question":"Immunovant'\u0131n lider \u00fcr\u00fcn\u00fc nedir?","answer":"IMVT-1402, Graves hastal\u0131\u011f\u0131 ve di\u011fer otoimm\u00fcn hastal\u0131klar i\u00e7in potansiyel en iyi s\u0131n\u0131f FcRn inhibit\u00f6r\u00fcd\u00fcr."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Immunovant hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \"IMVT\" sembol\u00fcn\u00fc aray\u0131n, limit emirleri kullanarak al\u0131m yap\u0131n ve pozisyonunuzu izleyin."},{"question":"Immunovant'\u0131n 2025 fiyat tahmini nedir?","answer":"2025 y\u0131l sonu i\u00e7in 18-22 $ aral\u0131\u011f\u0131nda fiyat bekleniyor, bu da %18-44 aras\u0131nda potansiyel y\u00fckseli\u015f anlam\u0131na geliyor."},{"question":"Immunovant'\u0131n en b\u00fcy\u00fck riskleri nelerdir?","answer":"Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, d\u00fczenleyici engeller, y\u00fcksek nakit t\u00fcketimi ve biyoteknoloji sekt\u00f6r\u00fcne \u00f6zg\u00fc volatilite ba\u015fl\u0131ca risklerdir."},{"question":"Yeni ba\u015flayanlar i\u00e7in yat\u0131r\u0131m \u00f6nerileri nelerdir?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir k\u0131sm\u0131yla ba\u015flay\u0131n, dolar maliyeti ortalamas\u0131 yap\u0131n, \u00f6nemli tarihler i\u00e7in uyar\u0131lar kurun ve uzun vadeli d\u00fc\u015f\u00fcn\u00fcn."},{"question":"Immunovant'\u0131n lider \u00fcr\u00fcn\u00fc nedir?","answer":"IMVT-1402, Graves hastal\u0131\u011f\u0131 ve di\u011fer otoimm\u00fcn hastal\u0131klar i\u00e7in potansiyel en iyi s\u0131n\u0131f FcRn inhibit\u00f6r\u00fcd\u00fcr."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Immunovant, Inc. (IMVT) Hisseleri Nas\u0131l Al\u0131n\u0131r - Immunovant, Inc. (IMVT) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immunovant, Inc. (IMVT) Hisseleri Nas\u0131l Al\u0131n\u0131r - Immunovant, Inc. (IMVT) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T18:20:39+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Immunovant, Inc. (IMVT) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Immunovant, Inc. (IMVT) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-25T18:20:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/\"},\"wordCount\":19,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/\",\"name\":\"Immunovant, Inc. (IMVT) Hisseleri Nas\u0131l Al\u0131n\u0131r - Immunovant, Inc. (IMVT) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"datePublished\":\"2025-08-25T18:20:39+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immunovant, Inc. (IMVT) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Immunovant, Inc. (IMVT) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Immunovant, Inc. (IMVT) Hisseleri Nas\u0131l Al\u0131n\u0131r - Immunovant, Inc. (IMVT) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/","og_locale":"tr_TR","og_type":"article","og_title":"Immunovant, Inc. (IMVT) Hisseleri Nas\u0131l Al\u0131n\u0131r - Immunovant, Inc. (IMVT) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T18:20:39+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Immunovant, Inc. (IMVT) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Immunovant, Inc. (IMVT) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-25T18:20:39+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/"},"wordCount":19,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/","name":"Immunovant, Inc. (IMVT) Hisseleri Nas\u0131l Al\u0131n\u0131r - Immunovant, Inc. (IMVT) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","datePublished":"2025-08-25T18:20:39+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-immunovant\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Immunovant, Inc. (IMVT) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Immunovant, Inc. (IMVT) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":349751,"slug":"how-to-buy-immunovant","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Immunovant, Inc. (IMVT) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Immunovant, Inc. (IMVT)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-immunovant\/"},"pt_AA":{"locale":"pt_AA","id":349749,"slug":"how-to-buy-immunovant","post_title":"Como comprar a\u00e7\u00f5es da Immunovant, Inc. (IMVT) - Investimento em a\u00e7\u00f5es da Immunovant, Inc. (IMVT)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-immunovant\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/349750","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=349750"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/349750\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334072"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=349750"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=349750"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=349750"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}